WHO IS EBMR?
Eastwood Bio-Medical Canada Inc. (EBMR) is a privately owned Canadian company engaged in the development and commercialization of safe and effective treatment for non-insulin dependent diabetes mellitus (NIDDM-Type II diabetes) and cancer. EBMR's core technologies include the NIDDM treatment, known as ELEOTIN®, and a recently discovered therapy for the treatment of stomach cancer, referred to as Gamma-C 200.
Incorporated in 1996, Dr. Youngsoo Kim is EBMR's Chief Executive Officer as well as a major shareholder. Dr. Kim is a scholar in the area of international finance and has served as a senior official in the Government of Korea. Located in Vancouver, EBMR is currently commercializing a patented 100% natural herbal treatment for controlling and regulating blood glucose levels.
Initially developed at the Julia McFarlane Diabetes Research Centre, ELEOTIN®has undergone numerous tests involving both animal and human subjects in various research facilities. ELEOTIN® has been proven to be safe and effective in the improvement of blood glucose levels in NIDDM patients.
It is composed of the extract of several medicinal plants, each playing a synergistic role in ELEOTIN®'s mechanism of action. Furthermore, ELEOTIN® supports a part of Yale University's Program for Basic Diabetes Research. Since ELEOTIN®is composed exclusively from natural herbs, it is sold as a dietary supplement and does not require a prescription.
As a supplement to a well-balanced diet, users have reported an improvement in general health. ELEOTIN® is now available for public consumption. In addition to ELEOTIN®, EBMR is working on developing a new treatment approach for stomach cancer.
Gamma C-200 refers to an aqueous extract from plant which has shown a specific and distinct effect on the inhibition or suppression of gastric tumor cell growth in vitro and in vivo, but not on normal cells. Our current stage of research will involve the identification and isolation of active chemical components and the confirmation of biological and pharmacological activity.
Following the completion of this stage, Gamma C-200 will be ready to enter preclinical trials. Eastwood Bio-Medical Canada Inc. will continue to explore advances in biotechnology and be an innovative leader in the fight against diabetes, cancer, and other related complications.